Initial combination therapy with ambrisentan and tadalafil in connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH): subgroup analysis from the AMBITION trial

Autor: JG Coghlan, Joan Albert Barberà, Vallerie V. McLaughlin, Marius M. Hoeper, Andrew J. Peacock, Julia Harris, Nazzareno Galiè, Hunter Gillies, Ambition investigators, Lewis J. Rubin, Gérald Simonneau, Jonathan Langley, Jean-Luc Vachiery, Masataka Kuwana, Karen L. Miller, Christiana Blair, Hossein Ardeschir Ghofrani, Adaani E. Frost

Publikováno v: Annals of the Rheumatic Diseases
Annals of the Rheumatic Diseases, 76 (7
Dipòsit Digital de la UB
Universidad de Barcelona
Recercat. Dipósit de la Recerca de Catalunya
instname

Background: Patients with connective tissue disease-associated pulmonary arterial hypertension (CTD-PAH), in particular systemic sclerosis (SSc), had an attenuated response compared with idiopathic PAH in most trials. Thus, there is uncertainty regar

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::152584aab046b45c6db6271128adf69d
http://europepmc.org/articles/PMC5530350

Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension

Autor: Galiè, Nazzareno, Barberà, Joan A., Frost, Adaani E., Ghofrani, Hossein-Ardeschir, Hoeper, Marius M., McLaughlin, Vallerie V., Peacock, Andrew J., Simonneau, Gérald, Vachiery, Jean-Luc, Grünig, Ekkehard, Oudiz, Ronald J., Vonk-Noordegraaf, Anton, White, R. James, Blair, Christiana, Gillies, Hunter, Miller, Karen L., Harris, Julia H.N., Langley, Jonathan, Rubin, Lewis J., Beghetti, Maurice, AMBITION Investigators

Publikováno v: New England Journal of Medicine, Vol. 373, No 9 (2015) pp. 834-844
Recercat. Dipósit de la Recerca de Catalunya
instname
New England Journal of Medicine
New England Journal of Medicine, Massachusetts Medical Society, 2015, 373 (9), pp.834-844. ⟨10.1056/NEJMoa1413687⟩
New England Journal of Medicine, 373(9), 834-844. Massachussetts Medical Society
Dipòsit Digital de la UB
Universidad de Barcelona
Galie, N, Barbera, J A, Frost, A E, Ghofrani, H A, Hoeper, M M, McLaughlin, V V, Peacock, A J, Simonneau, G, Vachiery, J L, Grunig, E, Oudiz, R J, Vonk-Noordegraaf, A, White, R J, Blair, C, Gillies, H, Miller, K L, Harris, J H N, Langley, J & Rubin, L J 2015, ' Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension ', New England Journal of Medicine, vol. 373, no. 9, pp. 834-844 . https://doi.org/10.1056/NEJMoa1413687

BACKGROUND: Data on the effect of initial combination therapy with ambrisentan and tadalafil on long-term outcomes in patients with pulmonary arterial hypertension are scarce. METHODS: In this event-driven, double-blind study, we randomly assigned, i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d04f624042d96ecd2082581401852405
http://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-124285